Bell's palsy is sudden one-sided facial weakness with no identifiable cause. Most cases recover well with standard treatment. A small number do not, and HBOT comes up in the conversation about persistent cases.
The evidence base for HBOT in Bell's palsy is thin. One favorable randomized trial from 1997 has not been replicated. Major neurology bodies do not recommend HBOT for Bell's palsy as standard care.
The FDA has cleared HBOT for 13 specific uses. Bell's palsy is not among them.
We walk through what's known below.
What Bell's palsy is
Bell's palsy affects roughly 40,000 Americans each year, per the National Institute of Neurological Disorders and Stroke. The condition involves sudden weakness of the muscles on one side of the face.
The cause is not fully known. The leading theory is viral reactivation — likely herpes simplex — causing inflammation of the seventh cranial (facial) nerve.
Most people recover well. Roughly 70% recover completely within six months, and another 15-20% recover with mild residual weakness (Peitersen 2002).
The remaining 10-15% have persistent facial weakness. These cases drive most of the patient interest in HBOT.
Standard treatment
The current standard is oral steroids (typically prednisone) within 72 hours of symptom onset. The Sullivan et al. 2007 trial — published in the New England Journal of Medicine — established this protocol.
The trial randomized 551 patients to prednisolone, acyclovir, both, or placebo. Prednisolone alone produced full recovery in 83% of patients at nine months vs 64% with placebo.
Antivirals (acyclovir, valacyclovir) are sometimes added but the evidence is weaker. Eye care — artificial tears, taping the eye shut at night — prevents corneal damage from incomplete blinking.
Physical therapy and facial exercises help recovery in some cases. Surgical decompression of the facial nerve is rarely performed and remains controversial.
The HBOT evidence base
The single most-cited trial for HBOT in Bell's palsy is Racic et al. 1997. The trial enrolled 79 patients and randomized them to HBOT or prednisone.
The HBOT arm received 30 sessions at 2.5 ATA. The prednisone arm received standard steroid taper. The HBOT group had a higher recovery rate at three weeks.
The trial has limits. The control was steroid alone, not HBOT plus steroid vs steroid alone. The protocol was 30 sessions at 2.5 ATA — a relatively high pressure.
More importantly, the result has not been replicated. Twenty-eight years later, no comparable randomized trial has been published.
A 2012 Cochrane review on HBOT for Bell's palsy could only identify the Racic trial as eligible. The review concluded that the evidence was insufficient to recommend HBOT.
What neurology bodies say
The American Academy of Neurology 2012 guidelines recommend oral steroids within 72 hours as the standard treatment. HBOT is not mentioned as a recommended option.
The Cochrane review 2012 found insufficient evidence to recommend HBOT for Bell's palsy. The 2019 update did not change this position.
The Undersea and Hyperbaric Medical Society does not list Bell's palsy among its 14 approved indications.
Major neurology departments at academic centers do not typically offer HBOT for Bell's palsy. The intervention is concentrated in off-label HBOT clinics rather than neurology practices.
The mechanism question
The biological argument for HBOT in Bell's palsy rests on the inflammation hypothesis. If the facial nerve is compressed by inflammation and edema, increased oxygen delivery might reduce the local injury.
HBOT does reduce inflammation in some controlled settings. Whether that translates to facial nerve recovery is the open question.
The competing intervention — steroids — works on the same mechanism more directly. Steroids reduce inflammation systemically and have decades of evidence in Bell's palsy.
For HBOT to add value, it would need to provide something beyond what steroids already deliver. The 1997 Racic trial does not establish this, since it compared HBOT to steroid rather than testing HBOT plus steroid against steroid alone.
What clinics charge
Off-label HBOT for Bell's palsy typically runs 20 to 40 sessions at 2.0-2.4 ATA. Per-session pricing usually runs $250 to $500 at hard-shell hospital-grade chambers from Sechrist Industries or Perry Baromedical.
A full course thus costs $5,000 to $20,000 out of pocket. Insurance does not cover HBOT for Bell's palsy.
Soft-shell 1.3 ATA programs at OxyHealth or Summit to Sea chambers run $50-100 per session. The mechanistic case at 1.3 ATA is weaker than at 2.0 ATA, given the much smaller arterial oxygen rise. Restore Hyper Wellness sites offer this tier broadly.
Our comparison of mild vs medical HBOT lays out the dose difference in detail.
When HBOT might be considered
The strongest case for HBOT in Bell's palsy is in patients with persistent weakness past three months who have not responded to standard care.
In acute Bell's palsy (first 72 hours), the evidence supports steroids. Adding HBOT to steroids has not been tested in a modern RCT. The cost-benefit is unclear.
In chronic Bell's palsy (past six months), recovery is unlikely with any treatment. HBOT cannot reverse established axonal injury. The most a patient should expect is modest residual improvement.
The honest answer for most patients: standard care within the first three days, observation, and patience. Most patients recover well without HBOT.
How to evaluate a clinic
Several questions cut through the marketing.
What is the rationale for HBOT in this case? If a patient has not yet completed a steroid course, that is the priority. HBOT does not substitute for steroids in acute Bell's palsy.
What is the chamber make and model? Look up the K-number on openFDA. Hospital-grade hard-shell chambers from Sechrist Industries or Perry Baromedical are the medical-grade standard.
What pressure and how many sessions? The 1997 Racic protocol was 30 sessions at 2.5 ATA. Anything radically different from this needs justification.
Is the clinic UHMS-accredited? Check the UHMS directory. Most accredited sites focus on FDA-approved uses.
What does the supervising physician say about the Cochrane review? A clinic that has no answer for the insufficient-evidence finding is selling rather than informing.
A note on adjunctive use
Some hyperbaric clinics market HBOT as an adjunct to standard care in acute Bell's palsy. The proposed mechanism is reducing nerve edema in the immediate inflammatory phase.
This is not unreasonable as a hypothesis. It is also not supported by published RCT data. No trial has tested HBOT plus steroids against steroids alone in Bell's palsy.
If a patient and physician agree to add HBOT alongside steroids in the first week, that is a defensible off-label decision. The cost is real and insurance will not cover it. The added benefit, if any, is unproven.
For most patients, the better use of the first week is full-dose steroids, eye protection, and follow-up with a neurologist. Adding HBOT does not change that priority list.
A note on the broader off-label market
The off-label HBOT market promotes a long list of neurological conditions, with Bell's palsy as one example. The evidence base for each varies. Bell's palsy is on the weaker end — one favorable trial, never replicated, against a backdrop of effective standard care.
Aviv Clinics and similar high-end programs do not specifically market a Bell's palsy protocol. Patients with persistent facial weakness sometimes enroll in their general 60-session "chronic condition" courses. There is no published trial evidence for HBOT in chronic Bell's palsy at any protocol.
We unpack the broader evidence-marketing gap in our Aviv evidence-vs-marketing analysis and the institutional silence analysis.
Bottom line
For acute Bell's palsy (first 72 hours), oral steroids are the standard. The 2007 Sullivan trial in NEJM is the definitive evidence base.
For persistent Bell's palsy past three months, HBOT has weak evidence and no insurance coverage. Cost runs $5,000-$20,000 for a course.
If you choose to try HBOT for persistent Bell's palsy, use a hard-shell hospital-grade chamber at 2.0-2.5 ATA under physician supervision. Understand the evidence is one 1997 trial.
Related Reading
- HBOT for ADHD: what the evidence actually shows
- HBOT for long COVID: Shamir RCT detailed analysis
- HBOT for PTSD: clinical trials update
- Institutional silence on HBOT
- Mild HBOT vs medical HBOT
Frequently asked questions
Is HBOT FDA-approved for Bell's palsy?
No. The FDA has cleared HBOT for 13 specific uses; Bell's palsy is not among them. Use of HBOT for Bell's palsy is off-label.
Does insurance cover HBOT for Bell's palsy?
No. No major US insurer covers HBOT for Bell's palsy. Patients pay out of pocket, typically $5,000 to $20,000 for a 20-40 session course.
How strong is the evidence?
Weak. The single most-cited trial is Racic et al. 1997, which favored HBOT over steroids. The trial has not been replicated. The 2012 Cochrane review found insufficient evidence to recommend HBOT.
What is the standard treatment for Bell's palsy?
Oral steroids (prednisone) within 72 hours of symptom onset. The Sullivan 2007 NEJM trial established this. Eye care prevents corneal damage. Most patients recover well with standard care.
Should I try HBOT if standard care doesn't work?
That's a discussion to have with your neurologist. For persistent weakness past three months, HBOT has weak evidence. The cost is real and not covered by insurance.
Medical disclaimer: This article is informational and does not constitute medical advice. HBOT carries real risks including ear barotrauma, oxygen toxicity, and chamber fire. Bell's palsy requires evaluation by a neurologist or primary care physician within the first 72 hours of symptom onset to determine the right standard treatment. The FDA has cleared HBOT for 13 specific uses; Bell's palsy is not among them.
-- The HBOT Finder Team